European study finds the abbott cardiomems sensor results in improved quality of life and 44% reduction in heart failure hospitalizations

Monitor-hf is the third randomized, controlled trial globally to show a significant health benefit for indicated heart failure patients cardiomems is a paperclip-sized sensor that can remotely flag to a patient's clinical team the early warning signs of worsening heart failure abbott park, ill., may 24, 2023 /prnewswire/ -- new data presented from an investigator-sponsored european trial found managing indicated1 heart failure patients with abbott's cardiomems™ hf system resulted in a significant1 improvement in patient-reported quality-of-life scores as early as three months after use with the remote monitoring sensor.
ABT Ratings Summary
ABT Quant Ranking